Discovery and Characterization of 6-{4-[3-(<i>R</i>)-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2<i>H</i>-pyridazin-3-one (CEP-26401, Irdabisant): A Potent, Selective Histamine H<sub>3</sub>Receptor Inverse Agonist
Robert L. Hudkins(State Street (United States)), Michael Williams, Mehran Yazdanian, Edward R. Bacon, Rita Raddatz, John P. Mallamo, Lars J. S. Knutsen, Mark A. Ator, Lisa D. Aimone, G. Moachon, Catherine Prouty, Michael J. Marino, Ming Tao(Peking University), Joanne R. Mathiasen, Nadine C. Becknell(NRG Oncology)
Cited by 68
Related Papers
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
|ACS Chemical Neuroscience|2011|436
Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma
|Molecular Cancer|2024|309
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives
|Journal of Medicinal Chemistry|1997|120
Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors
|Expert Opinion on Drug Discovery|2016|113